Epstein Secrets

nytimes.corn/2020/09/02/us/politics/melania-trump-emails.html> (9/2, Shear, 18.61M) reports that Stephanie Winston Wolkoff, who served as First Lady Melania Trump's senior adviser and "had previously been a close friend," alleges that the First Lady "used a personal email account and encrypted messaging apps li

ephanie Winston Wolkoff, who served as First Lady Melania Trump's senior adviser and "had previously been

https://www.nytimes.corn/2020/09/02/opinion/coronavirus-convalescent-plasma.html> (9/2, 18.61M), Daniela J. Lamas, a critical care doctor, questions the Food and Drug Administration's "emergency use authorization for convalescent plasma despite inadequate evidence." Lamas writes that possible treatments must undergo clinical tria

Used Personal Email For Official Business. The New York Times (9/2, Shear, 18.61M) reports that Stephanie Winston Wolkoff, who served as First Lady Melania Trump's senior adviser and "had previously been a close friend," alleges EFTA00149456 that the First Lady "used a personal email account and encrypted mes

phanie Winston Wolkoff, who served as First Lady Melania Trump's senior adviser and "had previously been a

or Efficacy Or Safety Of Convalescent Plasma. In an op-ed for the New York Times (9/2, 18.61M), Daniela J. Lamas, a critical care doctor, questions the Food and Drug Administration's "emergency use authorization for convalescent plasma despite inadequate evidence." Lamas writes that possible treatments must undergo clinical tria

Used Personal Email For Official Business. The New York Times (9/2, Shear, 18.61M) reports that Stephanie Winston Wolkoff, who served as First Lady Melania Trump's senior adviser and "had previously been a close friend," alleges that the First Lady "used a personal email account and encrypted messaging apps lik

phanie Winston Wolkoff, who served as First Lady Melania Trump's senior adviser and "had previously been a

or Efficacy Or Safety Of Convalescent Plasma. In an op-ed for the New York Times (9/2, 18.61M), Daniela J. Lamas, a critical care doctor, questions the Food and Drug Administration's "emergency use authorization for convalescent plasma despite inadequate evidence." Lamas writes that possible treatments must undergo clinical tria